Defining Cancer Drug Development Part II: A Discussion with FDA's Pazdur
This article was originally published in RPM Report
Executive Summary
FDA’s top oncology drug regulator says experience and history matter when making review decisions on supplemental indications for therapies already on the market.
You may also be interested in...
Swing for the Fences: FDA's Top Cancer Drug Official Urges "Home Run" Trial Designs for Targeted Therapies
When Richard Pazdur discussed ideas for a National Cancer Policy at an IoM event, one theme was unmistakable: if sponsors really believe what they say about targeted therapies for cancer, they should aim high with their clinical trial designs and endpoints.
Swing for the Fences: FDA's Top Cancer Drug Official Urges "Home Run" Trial Designs for Targeted Therapies
When Richard Pazdur discussed ideas for a National Cancer Policy at an IoM event, one theme was unmistakable: if sponsors really believe what they say about targeted therapies for cancer, they should aim high with their clinical trial designs and endpoints.
Carving REMS Out of Oncology? FDA, ASCO Plan Follow-Up Workshop
FDA and the oncology community will continue discussions about the role of REMS in cancer care. The agency is clearly taking pushback from providers seriously.